Ovid Therapeutics Says Preclinical Data of OV101 Shows Behavioral Improvements in Fragile X Syndrome Model

Ovid Therapeutics Says Preclinical Data of OV101 Shows Behavioral Improvements in Fragile X Syndrome Model

New York-based Ovid Therapeutics (OVID) reported Monday new positive preclinical data on OV101 showing normalization of behavioral abnormalities resembling those seen in people with Fragile X syndrome. “Treatment with OV101 results in significant behavioral improvements that are consistent across all behavioral endpoints tested,” said Matthew During, chief scientific officer. “We designed this study to deepen our understanding of the mechanisms of action and potential benefit of OV101 to treat patients […]

Read More ˃